Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats

References

• Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001;3:75–80.
   PubMed Web of Science ®Google Scholar
• Churcher I, Beher D, Best JD, et al. 4-Substituted cyclohexyl sulfones as potent, orally active g-secretase inhibitors. Bioorg Med Chem Lett 2006;16:280–4.
   PubMed Web of Science ®Google Scholar
• Borgegård T, Gustavsson S, Nilsson C, et al. Alzheimer's disease: presenilin 2-sparing γ-secretase inhibition is a tolerable Aβ peptide-lowering strategy. J Neurosci 2012;32(48):17297–305.
   PubMed Web of Science ®Google Scholar
• Best JD, Jay MT, Out F, et al. In vivo characterization of Aβ (40) changes in brain and cerebrospinal fluid using the novel g-secretase inhibitor N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 2006; 317:786–90.
   PubMed Web of Science ®Google Scholar
• Best JD, Smith DW, Reilly MA, et al. The novel g secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2007;320:552–8.
   PubMed Web of Science ®Google Scholar
• Shapiro JS, Stitler M, Wu G, et al. Cisterna magna cannulated rat model - effects of a gamma-secretase inhibitor on cerebrospinal fluid Aβ levels. J Neurosci Methods 2012;205:36–44.
   PubMed Web of Science ®Google Scholar
• Sato N, Imaizumi K, Manabe T, et al. Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 2001;276:2108–14.
   PubMed Web of Science ®Google Scholar
• Dahlgren KN, Manelli AM, Stine WB Jr, et al.. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046–53.
   PubMed Web of Science ®Google Scholar
• Younkin SG. The role of Abeta 42 in Alzheimer's disease. J Physiol 1998;92:289–92.
   Web of Science ®Google Scholar
• Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007;116:266–86.
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002;81:229–36.
   PubMed Web of Science ®Google Scholar
• Abramowski D, Wiederhold KH, Furrer U, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008;327:411–24.
   PubMed Web of Science ®Google Scholar
• Zheng H, Jiang M, Trumbauer ME, et al. Beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995;81:525–31.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan S, Price EA, Wu G, et al. In vivo beta-secretase 1 inhibition leads to brain A beta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 2008;324:957–69.
   PubMed Web of Science ®Google Scholar
• Wu G, Sankaranarayanan S, Montgomery DL, et al. Pharmacological applications of a novel neoepitope antibody to a modified amyloid precursor protein-derived β-secretase substrate. Protein Cell 2011;2:573–84.
   PubMedGoogle Scholar
• Wu G, Sankaranarayanan S, Hsieh S, et al. Decrease in brain soluble amyloid precursor protein beta (sAPPβ) in Alzheimer's disease cortex. J Neurosci Res 2011;89:822–32.
   PubMed Web of Science ®Google Scholar
• Wu G, Sankaranarayanan S, Tugusheva K, et al. Decrease in age-adjusted cerebrospinal fluid b-secretase activity in Alzheimer's subjects. Clin Biochem 2008;41:986–96.
   PubMed Web of Science ®Google Scholar
• Wu G, Sankaranarayanan S, Wong terization of plasma β-secretase (BACE1) activity and soluble amyloid recursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res 2012;90:2247–58.
   PubMed Web of Science ®Google Scholar
• Morgan C, Colombres M, Nuñez MT, Inestrosa NC. Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 2004;74:323–49.
   PubMedGoogle Scholar
• Klein AM, Kowall NW, Ferrante RJ. Neurotoxicity and oxidative damage of beta amyloid 1–42 versus beta amyloid 1–40 in the mouse cerebral cortex. Ann NY Acad Sci 1999;893: 314–20.
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Berger EP, Lansbury PT r. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693–7.
   PubMed Web of Science ®Google Scholar
• Pan XD, Zhu YG, Lin N, et al. Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease. Mol Neurodegener 2011;6:45.
   PubMed Web of Science ®Google Scholar
• Petrlova J, Hong HS, Bricarello DA, et al. A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution. Proteins 2011;79:402–16.
   PubMed Web of Science ®Google Scholar
• Riddell DR, Zhou H, Comery TA, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007;34:621–8.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kiyota T, Walsh SM, et al. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol 2008;181:3877–86.
   PubMed Web of Science ®Google Scholar
• Hawkins J, Harrison DC, Ahmed S, et al. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h. Neurodegener Dis 2012;8:455–64.
   Web of Science ®Google Scholar
• Shaw DE, Shearman MS, Teall MR, et al. 4-Substituted cyclohexyl sulfones as potent, orally active g-secretase inhibitors. Bioorg Med Chem Lett 2006;16:280–4.
   PubMed Web of Science ®Google Scholar
• Mehta PD, Pirttilä T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100–5.
   Google Scholar
• Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60(7):958–64.
   PubMed Web of Science ®Google Scholar
• Freeman SH, Raju S, Hyman BT, et al. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol 2007;66(4):264–71.
   PubMed Web of Science ®Google Scholar
• Mayeux R, Honig LS, Tang MX, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61(9):1185–90.
   PubMed Web of Science ®Google Scholar
• Schupf N, Tang MX, Fukuyama H, et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 2008;105(37):14052–57.
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369(4):341–50.
   PubMed Web of Science ®Google Scholar
• Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer's disease. Arch Neurol 2012; 69(11):1430–40.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30(6):317–25.
   PubMed Web of Science ®Google Scholar
• Rosen LB, Stone JA, Plump A, et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer's Dement 2006;2(3):S79.
   Google Scholar